SYRE Spyre Therapeutics Inc.

  1. Stocks
  2. Healthcare
  3. NASDAQ: SYRE

Price (delayed)

$32.41

Market cap

$1.17B

P/E Ratio

N/A

Dividend/share

N/A

EPS

-$49.12

Enterprise value

$982.44M

aeglea was founded in december of 2013 to develop engineered human enzymes invented in the laboratory of george georgiou, ph.d. of the university of texas at austin. the convergence of ...

Highlights
The company's equity has surged by 175% QoQ
Spyre Therapeutics's quick ratio has surged by 170% YoY and by 132% QoQ
SYRE's EPS has shrunk by 98% YoY but it is up by 35% QoQ
SYRE's revenue has shrunk by 62% YoY and by 16% QoQ
The gross profit has dropped by 62% year-on-year and by 16% since the previous quarter
Sector: Healthcare
Industry: Biotechnology
Website: http://aegleabio.com
Peers: OMER OMGA

Key stats

What are the main financial stats of SYRE
Market
Shares outstanding
36.15M
Market cap
$1.17B
Enterprise value
$982.44M
Valuations
Price to earnings (P/E)
N/A
Price to book (P/B)
0.71
Price to sales (P/S)
252.3
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
1,108.85
Earnings
Revenue
$886,000
EBIT
-$338.82M
EBITDA
-$337.85M
Free cash flow
-$99.44M
Per share
EPS
-$49.12
Free cash flow per share
-$14.42
Book value per share
$45.45
Revenue per share
$0.13
TBVPS
$49.57
Balance sheet
Total assets
$341.86M
Total liabilities
$73.29M
Debt
$0
Equity
$184.02M
Working capital
$309.55M
Liquidity
Debt to equity
0
Current ratio
10.68
Quick ratio
10.62
Net debt/EBITDA
0.56
Margins
EBITDA margin
-38,132.3%
Gross margin
100%
Net margin
-38,238.1%
Operating margin
-27,348%
Efficiency
Return on assets
-160.4%
Return on equity
N/A
Return on invested capital
N/A
Return on capital employed
-109.3%
Return on sales
-38,241.1%
Dividend
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A

SYRE stock price

How has the Spyre Therapeutics stock price performed over time
Intraday
-8.91%
1 week
-13.55%
1 month
-15.58%
1 year
710.25%
YTD
50.6%
QTD
-14.55%

Financial performance

How have Spyre Therapeutics's revenue and profit performed over time
Revenue
$886,000
Gross profit
$886,000
Operating income
-$242.3M
Net income
-$338.79M
Gross margin
100%
Net margin
-38,238.1%
Spyre Therapeutics's operating income has shrunk by 186% YoY and by 12% QoQ
SYRE's revenue has shrunk by 62% YoY and by 16% QoQ
The gross profit has dropped by 62% year-on-year and by 16% since the previous quarter
Spyre Therapeutics's net margin has decreased by 37% QoQ

Growth

What is Spyre Therapeutics's growth rate over time

Valuation

What is Spyre Therapeutics stock price valuation
P/E
N/A
P/B
0.71
P/S
252.3
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
1,108.85
SYRE's EPS has shrunk by 98% YoY but it is up by 35% QoQ
The company's equity has surged by 175% QoQ
SYRE's P/B is 66% below its 5-year quarterly average of 2.1
SYRE's revenue has shrunk by 62% YoY and by 16% QoQ

Efficiency

How efficient is Spyre Therapeutics business performance
Spyre Therapeutics's ROA has plunged by 69% YoY but it has increased by 22% from the previous quarter
SYRE's ROS is down by 37% QoQ

Dividends

What is SYRE's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A

There are no recent dividends present for SYRE.

Financial health

How did Spyre Therapeutics financials performed over time
Spyre Therapeutics's quick ratio has surged by 170% YoY and by 132% QoQ
SYRE's current ratio has soared by 151% YoY and by 133% QoQ
Spyre Therapeutics's debt is 100% lower than its equity
The company's equity has surged by 175% QoQ
Spyre Therapeutics's debt has shrunk by 100% YoY

All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.